two articles appeared at about the same time, so I am interested in seeing what our community makes of them.
first, Bryan Johnson announces that he has ended his own rapamycin regimen, due to benefits being outweighed by the side-effects.
next, the PEARL trial (Aging-US) randomized healthy 50-85 y/o volunteers in a 48 week, placebo controlled, 5 mg/week versus 10 mg/week trial, that failed to meet its primary endpoint, with no change in visceral fat.
there were benefits in the subgroup analysis, with women taking 10 mg/week gaining lean mass and reporting less pain, whereas men saw no benefit.
the authors work for AgelessRx, which sells the prescription.
not saying that invalidates anything, but it’s hard to ignore when reading their subgroup claims.
for reference the mouse studies have shown ~14-26% median lifespan extension in three NIA ITP studies, but extrapolating from that to what one might expect in a human trial is not a straightforward matter.
No pressure to change what you're doing, but I'm curious as to how people are thinking about these results, in terms of what they mean for the rapamycin trials in general.